| AGENUS INC. DL-,01 |
| USA |
| Gesundheit |
| US00847G8042 / A403RK |
| AJ8 (Frankfurt) / AGEN (NASDAQ) |
| FRA:AJ8, ETR:AJ8, AJ8:GR, NASDAQ:AGEN |
| - |
| https://agenusbio.com/ |
|
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies to treat cancer and infectious diseases. The company specializes in activating the body's immune system through advanced therapeutic approache..
>Volltext.. |
| 128.23 Mio. EUR |
| 356.47 Mio. EUR |
| 106.55 Mio. EUR |
| 13.06 Mio. EUR |
| 55.57 Mio. EUR |
| 1.49 EUR |
| 261.89 Mio. EUR |
| 30.1 Mio. EUR |
| - |
| 0.14 |
| 16.54% |
| - |
| - |
| - |
| - |
| - |
| AGENUS |
| 16.05.26 |
|
||||
|
||||
|